Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
MENLO PARK, Calif., Nov. 09, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in New York City. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858.356.5932 [email protected]
